Globus Medical, Inc.
GMED
Positions held
Your positionsGMED isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Globus Medical operates in the growing medical devices industry, focusing on innovative solutions that enhance patient outcomes, which positions it well against competitors.
- Revenue increased by 4% compared to the prior quarter, reaching $790 million.
- Operating margin expanded to 24.8%, reflecting improved efficiency.
- The company's earnings growth has declined significantly, with a decrease of 26.2% year-over-year, raising concerns about profitability.
- The current score indicates a 'Sell' signal with a score of -10.00, suggesting negative market sentiment.
- Net income for 2026-Q1 was $124.302 million, down from $151.569 million in 2026-Q2, indicating a downward trend.
Fundamentals
| Market cap | $9.85B | Enterprise value | $9.36B | Trailing P/E | 18.80 | Forward P/E | 13.58 |
| PEG | 1.49 | Price / book | 2.06 | Beta | 0.96 | Dividend yield | 0.00% |
| Revenue growth | 5.9% | Earnings growth | -26.2% | Gross margin | 69.0% | Operating margin | 24.8% |
| Profit margin | 17.0% | ROE | 11.8% | ROA | 8.7% | Debt / equity | 0.02 |
| Current ratio | 4.62 | Free cash flow | $554.19M | Analyst recommendation | buy | Mean target | $100.92 |
| 52w high | $101.40 | 52w low | $56.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $790M | $760M | $826M | $769M | $745M |
| Op margin | 24.8% | 21.3% | 21.9% | 17.6% | 16.5% |
| Net income | $152M | $124M | $141M | $119M | $203M |
| Gross margin | 69.4% | 69.2% | 68.4% | 67.2% | 66.6% |
| Gross profit | $548M | $526M | $565M | $517M | $497M |
| Operating income | $195M | $162M | $181M | $135M | $123M |
- Revenue +4% vs prior quarter ($790M vs $760M).
- Gross margin 69.4% (was 69.2% prior quarter).
- Operating margin expanded to 24.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.9B | $2.5B | $1.6B | $1.0B | — |
| Op margin | 18.3% | 8.7% | 12.8% | 23.1% | — |
| Net income | $538M | $103M | $123M | $190M | — |
| Gross margin | 67.4% | 58.9% | 65.1% | 74.2% | — |
| Gross profit | $2.0B | $1.5B | $1.0B | $759M | — |
| Operating income | $537M | $219M | $201M | $236M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Is it the Right Time to Add Phibro Stock to Your Portfolio?
2026-10-08 · Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
2026-10-08 · Reasons to Retain Hims & Hers Stock in Your Portfolio for Now
2026-10-08 · Should Globus Medical's Expanding Musculoskeletal Pipeline and Cash-Funded Growth Strategy Matter to GMED Investors?
2026-10-08 · 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
2026-10-08 · Here's Why You Should Retain WAT Stock in Your Portfolio for Now
2026-10-08 · Globus Medical (GMED) Stock Sees Modest Fair Value Cut As Analysts Split On Outlook
2026-10-07 · Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
2026-10-07 · BDX Expands U.S. Manufacturing With $19B Healthcare Investment
2026-10-07 · Reasons to Hold HealthEquity Stock in Your Portfolio for Now
2026-10-07 · Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
2026-10-07 · Charles River Gains 75.8% in a Year: What's Driving the Rally?
Price (daily)
Full chart · RSI · MACD · patterns